Telomir Pharmaceuticals Inc
Research Telomir Pharmaceuticals Inc (TELO) on Bullrun: market cap USD 81.15M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTELO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 81.15M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 990.95K
- Free cash flow-USD 1.77M
Valuation Snapshot
latest market cap is USD 81.15M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 10.41M | -USD 3.69M | n/a | -0.33 | USD 7.29M | n/a | USD 5.91M |
| FY2024 | USD 0 | -USD 16.53M | -USD 5.07M | n/a | -0.56 | USD 1.27M | n/a | USD 643.04K |
| FY2023 | n/a | -USD 13.07M | n/a | n/a | 0.48 | USD 1.23K | USD 101.00K | USD 3.44M |
| FY2022 | n/a | -USD 854.15K | n/a | n/a | -0.03 | USD 1.42K | n/a | -USD 937.28K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 81.15M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 45.73M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 122.62M | n/a | n/a | n/a |
About Telomir Pharmaceuticals Inc
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Telomir Pharmaceuticals Inc's market cap?
Telomir Pharmaceuticals Inc's market capitalization is USD 81.15M.
What does Telomir Pharmaceuticals Inc do?
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc.